


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:


LISTING OF CLAIMS:

1-11. (canceled).

12. (currently amended): The A compound according to claim 10, wherein the compound is the compound represented by formula (Ib-1)



wherein Q is alkyl which may have a substituent(s) or a cyclic ring which may have a substituent(s), Z is a nitrogen atom, Y^1 is



wherein E^1 and E^2 are each independently a hydrogen atom(s) or a substituent(s), X is an oxygen atom or a sulfur atom, left-pointing arrow binds to ring D, right-pointing arrow binds to Q, W is a single bond, R is a hydrogen atom(s) or a substituent (s), R^1 is a hydrogen atom(s) or a substituent(s), R^2 is C1-6 alkyl which is substituted with 1-5 halogen atom(s), G is -O- or -S-, m is an integer of 1-3, r is an integer of 1-2, s is an integer of 1-4, in which the sum of r and s is below 5.

other symbols have the same meanings as in claim 1, 6 and 10, and

AND PRELIMINARY AMENDMENT

Attorney Docket No.: Q94625

Application No.: 10/577,047

wherein

- (1) N-{4-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]pyrimidin-2-yl}-N'-phenylurea,
- (2) N-{4-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]pyrimidin-2-yl}-N'-(4-chlorophenyl)urea,
- (3) N-{4-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]pyrimidin-2-yl}-N'-(3-chlorophenyl)urea and
- (4) N-{4-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]pyrimidin-2-yl}-2-thiophenecarboxamide are excepted.

13. (currently amended): The compound according to claim 1012, wherein the compound is

- (1) N-{4-[2,5-bis(difluoromethoxy)phenyl]pyrimidin-2-yl}thiophene-2-carboxamide,
- (2) N-{4-[2,5-bis(difluoromethoxy)phenyl]pyrimidin-2-yl}-N'-isopropylurea,
- (3) N-{4-[2,5-bis(difluoromethoxy)phenyl]pyrimidin-2-yl}methanesulfonamide,
- (4) N-{4-[2,5-bis(difluoromethoxy)phenyl]pyrimidin-2-yl}benzenesulfonamide,
- (5) N-{4-[2,5-bis(difluoromethoxy)phenyl]pyrimidin-2-yl}-1-phenylmethanesulfonamide,
- (6) N-{4-[2,5-bis(difluoromethoxy)phenyl]pyrimidin-2-yl}-4-methylbenzenesulfonamide,
- (7) N-{4-[2,5-bis(difluoromethoxy)phenyl]pyrimidin-2-yl}-3-methylbenzenesulfonamide,

AND PRELIMINARY AMENDMENT

Attorney Docket No.: Q94625

Application No.: 10/577,047

(8) N-{4-[2,5-bis(difluoromethoxy)phenyl]pyrimidin-2-yl}-3,5-dimethylbenzenesulfonamide,

(9) N-{4-[2,5-bis(difluoromethoxy)phenyl]pyrimidin-2-yl}-3,5-dichlorobenzenesulfonamide,

(10) N-{4-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]pyrimidin-2-yl}benzenesulfonamide,

(11) N-{4-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]pyrimidin-2-yl}-4-methylbenzenesulfonamide,

(12) N-{4-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]pyrimidin-2-yl}-N-methylbenzenesulfonamide,

(13) N-{4[2,5-bis(2,2,2-trifluoroethoxy)phenyl]pyrimidin-2-yl}-N,4-dimethylbenzenesulfonamide,

(14) N-{4-[2,5-bis(difluoromethoxy)phenyl]pyrimidin-2-yl}-N-methylbenzenesulfonamide,

(15) N-benzyl-N-{4-[2,5-bis(difluoromethoxy)phenyl]pyrimidin-2-yl}methanesulfonamide,

(16) N-{4-[2,5-bis(difluoromethoxy)phenyl]pyrimidin-2-yl}-N-ethylbenzenesulfonamide,

(17) N-{4-[2,5-bis(difluoroemethoxy)phenyl]pyrimidin-2-yl}-N-propylbenzenesulfonamide,

(18) N-{4-[2,5-bis(difluoromethoxy)phenyl]pyrimidin-2-yl}-N-isobutylbenzenesulfonamide,

AND PRELIMINARY AMENDMENT

Attorney Docket No.: Q94625

Application No.: 10/577,047

(19) N-{4-[2,5-bis(difluoromethoxy)phenyl]pyrimidin-2-yl}-N-(2-methoxyethyl)benzenesulfonamide,

(20) 4-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]-N-ethyl-2-pyrimidinamine,

(21) N-benzyl-4-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]-N-methyl-2-pyrimidinamine, or

(22) N-benzyl-4-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]-2-pyrimidinamine.

14. **(currently amended):** A pharmaceutical composition comprising of the compound represented by formula (I)-(Ib-1) according to claim 412, a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof, and a pharmaceutically acceptable carrier or diluent.

15. **(original):** The pharmaceutical composition according to claim 14, wherein the pharmaceutical composition is preventive and/or therapeutic agent for mitochondrial benzodiazepine receptor mediated disease.

16. **(original):** The pharmaceutical composition according to claim 15, wherein the mitochondrial benzodiazepine receptor mediated disease is a disease caused by stress.

17. **(original):** The pharmaceutical composition according to claim 16, wherein the disease caused by stress is a central nervous system disease caused by stress, a respiratory system disease caused by stress and/or a digestive system disease caused by stress.

AND PRELIMINARY AMENDMENT

Attorney Docket No.: Q94625

Application No.: 10/577,047

18. **(original):** The pharmaceutical composition according to claim 17, wherein the central nervous system disease caused by stress is anxiety-related disease, sleep disorder, depression and/or epilepsy, a respiratory system disease caused by stress is asthma, a digestive system disease caused by stress is irritable bowel syndrome.

19. **(currently amended):** A pharmaceutical composition combining of the compound represented by formula ~~(I)-(Ib-1)~~ according to claim ~~112~~, a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof and one kind or more kind selected from antianxiety drugs, antidepressant drugs, antiparkinson drugs, therapeutic drugs for schizophrenia, antiepileptic drugs, therapeutic drugs for asthma, therapeutic drugs for peptic ulcer, adjustive drugs for gastrointestinal function, antidiarrheals, evacuants, antihypertensive drugs, antiarrhythmic drugs, inotropic drugs and therapeutic drugs for urination disorder.

20. **(currently amended):** A method for prevention and/or treatment for a mitochondrial benzodiazepine receptor mediated disease in mammals, which comprises administering an effective amount of the compound represented by formula ~~(I)-(Ib-1)~~ according to claim ~~112~~, a salt thereof, an N-oxide, a solvate or a prodrug thereof to the mammals.

21. **(canceled).**